Pfizer begins Phase 2 and 3 trial of Covid-19 antiviral Paxlovid in children ages 6 to 17

The new trials will evaluate how safe and effective the treat will be for children that have confirmed cases of Covid-19. This trial will consist of 140 people and they are to be separated into two different cohorts in order to determine how Paxlovid will effect them based on weight. In addition to evaluating the safety, experts are making it a point to study how the drug moves throughout the body.

To read more, click here.

Leave a Reply

Your email address will not be published.